CNS Ion Channel Liability Panel
The ApconiX CNS Ion Channel Liability Panel (iLA CNS) is a focused automated patch-clamp screening service designed to screen compounds for potential ion-channel-mediated CNS liabilities early in drug discovery, particularly when a specific concern has not yet been identified. The panel assesses compound activity across seven selected CNS-associated ion channels, helping project teams flag possible risks and decide whether more targeted follow-up testing is needed.
Why Assess CNS Ion Channel Liability Early?
It’s especially important to determine any adverse effects on the CNS early in the drug discovery pipeline as they occur frequently.
Screening for activity against ion channel targets (key in the functioning of the CNS) can help determine risk.
Negative effects on the CNS are broad, spanning from seizure to mood disturbance, so assessment of ion channel liability is crucial for drugs that cross the blood brain barrier.
We can help you identify potential CNS liabilities early on in your critical path by deploying our panel of CNS relevant ion channels according to your preferred screening approach.
Our iLA CNS panel is a suggested panel of 7 ion channels that cover a wide range of ion channel families and CNS adverse effects.
What Does the CNS Ion Channel Liability Panel Include?
You can view our panel of fully customisable seizure-associated ion channels in the table below:
| Panel | NaV1.1 | NaV1.2 | NaV1.6 | KV1.1 | KV2.1 | KV3.1 | KV4.2 | KV7.2/7.3 | KV7.3/7.5 | KCa1.1 | KCa4.1 | CaV2.1 |
GABA α1β2γ2 |
Nicotinic α4β2 |
NMDA 1/2A |
TREK1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CNS Panel
|
● | Not included | Not included | ● | Not included | Not included | Not included | ● | Not included | Not included | Not included | ● | ● | ● | ● | Not included |
Assess risk, understand underlying biological mechanisms and proceed with the right drug candidates with ApconiX. Our team can offer you diverse expertise in hiPSC-neuronal cell models, ion channel electrophysiology and project toxicology.
Benefits of the CNS Ion Channel Liability Panel
- A rapid turnaround of 14 days (from when we receive your compound) for high-quality profiling of ion channels
- Reduced costs on animal model studies (which do not always translate well to human) with our high-throughput assays
- An expert team of scientists on hand to customise our service and help guide you to the next stage of the process
Study Requirements, Data and Turnaround
- We require 2-3mg compound for the ion channel panel
- Our reports provide IC50 values for each compound generated by 4 – 6pt concentration-response curves which are generated using automated patch-clamp technology (Patchliner, Nanion Technologies or QPatch II, Sophion Biosciences). Patchliner and QPatch II achieve Giga-Ohm seal resistances resulting in excellent data quality
- Full reports are delivered within 2 weeks of receipt of compound
We are here to provide expert advice. If any concerns are highlighted in the results of any of our assays, our expert scientific team are on hand to discuss possible next steps.
Related CNS Ion Channel Resources:
